Protein and siRNA delivery by transportan and transportan 10 into colorectal cancer cell lines

Folia Histochemica et Cytobiologica

Volumn 52, Issue 4, 2014, Pages 270-280

  Wierzbicki, Piotr M ^a   Kogut Wierzbicka, Marzena ^a   Ruczynski, Jaroslaw ^b   Siedlecka Kroplewska, Kamila ^a   Kaszubowska, Lucyna ^a   Rybarczyk, Agnieszka ^a   Alenowicz, Magdalena ^b   Rekowski, Piotr ^b   Kmiec, Zbigniew ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITY OF GDA SK   (Poland)

Author keywords

Apoptosis; Cell cycle; CPP; HCT116; HT29; SASH1; siRNA; TP10; Transportan

Indexed keywords

BREFELDIN A; CELL PENETRATING PEPTIDE; LIPOCORTIN 5; MESSENGER RNA; SMALL INTERFERING RNA; STREPTAVIDIN; TRANSPORTAN; TRANSPORTAN 10; UNCLASSIFIED DRUG; GALANIN; HYBRID PROTEIN; SASH1 PROTEIN, HUMAN; TRANSPORTAN-10; TUMOR SUPPRESSOR PROTEIN; WASP VENOM;

ARTICLE; BIOTINYLATION; CANCER CELL CULTURE; CANCER STAGING; CELL CYCLE; CELL TRANSPORT; CELL VACUOLE; CELL VIABILITY; CELLULAR DISTRIBUTION; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE; GENE TARGETING; HCT116 CELL LINE; HT 29 CELL LINE; HUMAN; HUMAN CELL; INCUBATION TIME; METASTATIC COLORECTAL CANCER; MTT ASSAY; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; SASH1 GENE; BIOASSAY; CELL SURVIVAL; CHEMISTRY; COLORECTAL NEOPLASMS; DRUG EFFECTS; GENE TRANSFER; LD50; METABOLISM; STANDARDS;

BIOLOGICAL ASSAY; CELL CYCLE; CELL SURVIVAL; CELL-PENETRATING PEPTIDES; COLORECTAL NEOPLASMS; GALANIN; GENE TRANSFER TECHNIQUES; HCT116 CELLS; HT29 CELLS; HUMANS; LETHAL DOSE 50; RECOMBINANT FUSION PROTEINS; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEINS; WASP VENOMS;

EID: 84921837344     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.a2014.0035     Document Type: Article

References (53)

1. Saar K, Lindgren M, Hansen M et al. Cell-penetrating peptides: a comparative membrane toxicity study. Anal Biochem. 2005; 345: 55-65.
2. Cardozo AK, Buchillier V, Mathieu M et al. Cell-permeable peptides induce dose-and length-dependent cytotoxic effects. Biochim Biophys Acta. 2007; 1768: 2222-2234.
3. Amantana A, Moulton HM, Cate ML et al. Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjug Chem. 2007; 18: 1325-1331.
4. Moschos SA, Jones SW, Perry MM et al. Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem. 2007; 18: 1450-1459.
5. Astriab-Fisher A, Sergueev D, Fisher M, Shaw BR, Juliano RL. Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: effects on cellular uptake, binding to target sequences, and biologic actions. Pharm Res. 2002; 19: 744-754.
6. Begley R, Liron T, Baryza J, Mochly-Rosen D. Biodistribution of intracellularly acting peptides conjugated reversibly to Tat. Biochem Biophys Res Commun. 2004; 318: 949-954.
7. Futaki S, Suzuki T, Ohashi W et al. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem. 2001; 276: 5836-5840.
8. Soomets U, Lindgren M, Gallet X et al. Deletion analogues of transportan. Biochim Biophys Acta. 2000; 1467: 165-176.
9. Ruczynski J, Wierzbicki PM, Kogut-Wierzbicka M, Mucha P, Siedlecka-Kroplewska K, Rekowski P. Cell-penetrating peptides as a promising tool for delivery of various molecules into the cells. Folia Histochem Cytobiol. 2014; 52. doi: 10. 5603/FHC. a2014. 0034.
10. Hallbrink M, Floren A, Elmquist A, Pooga M, Bartfai T, Langel U. Cargo delivery kinetics of cell-penetrating peptides. Biochim Biophys Acta. 2001; 1515: 101-109.
11. Gros E, Deshayes S, Morris MC et al. A non-covalent peptide-based strategy for protein and peptide nucleic acid transduction. Biochim Biophys Acta. 2006; 1758: 384-393.
12. Morris MC, Deshayes S, Heitz F, Divita G. Cell-penetrating peptides: from molecular mechanisms to therapeutics. Biol Cell. 2008; 100: 201-217.
13. Pooga M, Kut C, Kihlmark M et al. Cellular translocation of proteins by transportan. FASEB J. 2001; 15: 1451-1453.
14. Deshayes S, Morris MC, Divita G, Heitz F. Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell Mol Life Sci. 2005; 62: 1839-1849.
15. Padari K, Saalik P, Hansen M et al. Cell transduction pathways of transportans. Bioconjug Chem. 2005; 16: 1399-1410.
16. Saalik P, Niinep A, Pae J et al. Penetration without cells: membrane translocation of cell-penetrating peptides in the model giant plasma membrane vesicles. J Control Release. 2011; 153: 117-125.
17. Duchardt F, Fotin-Mleczek M, Schwarz H, Fischer R, Brock R. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic. 2007; 8: 848-866.
18. Fretz MM, Penning NA, Al-Taei S et al. Temperature-, concentration-and cholesterol-dependent translocation of L-and D-octa-arginine across the plasma and nuclear membrane of CD34+ leukaemia cells. Biochem J. 2007; 403: 335-342.
19. Jiao CY, Delaroche D, Burlina F, Alves ID, Chassaing G, Sagan S. Translocation and endocytosis for cell-penetrating peptide internalization. J Biol Chem. 2009; 284: 33957-33965.
20. Dunkin CM, Pokorny A, Almeida PF, Lee HS. Molecular dynamics studies of transportan 10 (tp10) interacting with a POPC lipid bilayer. J Phys Chem B. 2011; 115: 1188-1198.
21. Song J, Kai M, Zhang W et al. Cellular uptake of transportan 10 and its analogs in live cells: Selectivity and structure-activity relationship studies. Peptides. 2011; 32: 1934-1941.
22. Madani F, Lindberg S, Langel U, Futaki S, Graslund A. Mechanisms of cellular uptake of cell-penetrating peptides. J Biophys. 2011; 2011: 414729.
23. Emans N, Zimmermann S, Fischer R. Uptake of a fluorescent marker in plant cells is sensitive to brefeldin A and wortmannin. Plant Cell. 2002; 14: 71-86.
24. Frankel G, Gil S, Dougan G. Effect of deoxymannojirimycin and Brefeldin A on Yersinia pseudotuberculosis invasin-eukaryotic cell interaction. Microb Pathog. 1995; 19: 421-427.
25. Veldhoen S, Laufer SD, Restle T. Recent developments in peptide-based nucleic acid delivery. Int J Mol Sci. 2008; 9: 1276-1320.
26. Kocic I, Ruczynski J, Szczepanska R et al. Cell-penetrating peptides modulate the vascular action of phenylephrine. Pharmacol Rep. 2011; 63: 195-199.
27. Eudes F, Chugh A. Cell-penetrating peptides: From mammalian to plant cells. Plant Signal Behav. 2008; 3: 549-550.
28. Siedlecka-Kroplewska K, Szczerba A, Lipinska A, Slebioda T, Kmiec Z. 3-Fluoromethcathinone, a structural analog of mephedrone, inhibits growth and induces cell cycle arrest in HT22 mouse hippocampal cells. J Physiol Pharmacol. 2014; 65: 241-246.
29. Weber PC, Ohlendorf DH, Wendoloski JJ, Salemme FR. Structural origins of high-affinity biotin binding to streptavidin. Science. 1989; 243: 85-88.
30. Korber C, Horstmann H, Satzler K, Kuner T. Endocytic structures and synaptic vesicle recycling at a central synapse in awake rats. Traffic. 2012; 13: 1601-1611.
31. Ezzat K, Helmfors H, Tudoran O et al. Scavenger receptor-mediated uptake of cell-penetrating peptide nanocomplexes with oligonucleotides. FASEB J. 2012; 26: 1172-1180.
32. Wierzbicki PM, Klacz J, Rybarczyk A et al. Identification of a suitable qPCR reference gene in metastatic clear cell renal cell carcinoma. Tumour Biol. 2014. doi: 10. 1007/s13277-014-2566-9.
33. El-Andaloussi S, Jarver P, Johansson HJ, Langel U. Cargo-dependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study. Biochem J. 2007; 407: 285-292.
34. Saleh AF, Aojula H, Arthanari Y, Offerman S, Alkotaji M, Pluen A. Improved Tat-mediated plasmid DNA transfer by fusion to LK15 peptide. J Control Release. 2010; 143: 233-242.
35. Lim KJ, Sung BH, Shin JR et al. A cancer specific cell-penetrating peptide, BR2, for the efficient delivery of an scFv into cancer cells. PLoS One. 2013; 8: e66084.
36. Jones SW, Christison R, Bundell K et al. Characterisation of cell-penetrating peptide-mediated peptide delivery. Br J Pharmacol. 2005; 145: 1093-1102.
37. Kam Y, Rubinstein A, Nissan A, Halle D, Yavin E. Detection of endogenous K-ras mRNA in living cells at a single base resolution by a PNA molecular beacon. Mol Pharm. 2012; 9: 685-693.
38. Zhang H, Zhang S, He H, Zhao W, Chen J, Shao RG. GAP161 targets and downregulates G3BP to suppress cell growth and potentiate cisplaitin-mediated cytotoxicity to colon carcinoma HCT116 cells. Cancer Sci. 2012; 103: 1848--1856.
39. Barany-Wallje E, Gaur J, Lundberg P, Langel U, Graslund A. Differential membrane perturbation caused by the cell penetrating peptide Tp10 depending on attached cargo. FEBS Lett. 2007; 581: 2389-2393.
40. Eggimann GA, Buschor S, Darbre T, Reymond JL. Convergent synthesis and cellular uptake of multivalent cell penetrating peptides derived from Tat, Antp, pVEC, TP10 and SAP. Org Biomol Chem. 2013; 11: 6717-6733.
41. Arukuusk P, Parnaste L, Oskolkov N et al. New generation of efficient peptide-based vectors, NickFects, for the delivery of nucleic acids. Biochim Biophys Acta. 2013; 1828: 1365--1373.
42. Fisher L, Soomets U, Cortes Toro V et al. Cellular delivery of a double-stranded oligonucleotide NFkappaB decoy by hybridization to complementary PNA linked to a cell-penetrating peptide. Gene Ther. 2004; 11: 1264-1272.
43. Moulton HM. Cell-penetrating peptides enhance systemic delivery of antisense morpholino oligomers. Methods Mol Biol. 2012; 867: 407-414.
44. Nasrolahi Shirazi A, Tiwari R, Chhikara BS, Mandal D, Parang K. Design and biological evaluation of cell-penetrating peptide-doxorubicin conjugates as prodrugs. Mol Pharm. 2013; 10: 488-499.
45. Jang YL, Yun UJ, Lee MS et al. Cell-penetrating peptide mimicking polymer-based combined delivery of paclitaxel and siRNA for enhanced tumor growth suppression. Int J Pharm. 2012; 434: 488-493.
46. Tints K, Prink M, Neuman T, Palm K. LXXLL peptide converts transportan 10 to a potent inducer of apoptosis in breast cancer cells. Int J Mol Sci. 2014; 15: 5680-5698.
47. Juliano R, Alam MR, Dixit V, Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res. 2008; 36: 4158-4171.
48. Heitz F, Morris MC, Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol. 2009; 157: 195-206.
49. Lehto T, Simonson OE, Mager I et al. A peptide-based vector for efficient gene transfer in vitro and in vivo. Mol Ther. 2011; 19: 1457-1467.
50. Raagel H, Saalik P, Hansen M, Langel U, Pooga M. CPP-protein constructs induce a population of non-acidic vesicles during trafficking through endo-lysosomal pathway. J Control Release. 2009; 139: 108-117.
51. Madani F, Abdo R, Lindberg S et al. Modeling the endosomal escape of cell-penetrating peptides using a transmem-brane pH gradient. Biochim Biophys Acta. 2013; 1828: 1198--1204.
52. Nebenfuhr A, Ritzenthaler C, Robinson DG, Brefeldin A. Deciphering an enigmatic inhibitor of secretion. Plant Physiol. 2002; 130: 1102-1108.
53. Rinne J, Albarran B, Jylhava J et al. Internalization of novel non-viral vector TAT-streptavidin into human cells. BMC Biotechnol. 2007; 7: 1.